CD19 and B-cell acute lymphoblastic leukemia: Prior to initiation of these trials, two infants with relapsed refractory CD19+ B-cell acute lymphoblastic leukemia were treated with TALEN-mediated CD52 and TCR knockout CD19 CAR T cells in combination with anti-CD52 therapy [58].